146 related articles for article (PubMed ID: 28179304)
1. IMP3 Expression in Borderline Tumors of the Ovary.
El-Balat A; Sänger N; Karn T; Becker S; Holtrich U; Muallem Z; Arsenic R
Anticancer Res; 2017 Feb; 37(2):583-588. PubMed ID: 28179304
[TBL] [Abstract][Full Text] [Related]
2. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.
Bi R; Shen X; Zhang W; Cheng Y; Feng Z; Cai X; Yang W
Diagn Pathol; 2016 Feb; 11():17. PubMed ID: 26837693
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.
Oktem G; Sanci M; Bilir A; Yildirim Y; Kececi SD; Ayla S; Inan S
Int J Gynecol Cancer; 2012 Jan; 22(1):23-9. PubMed ID: 22080880
[TBL] [Abstract][Full Text] [Related]
4. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
5. TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.
El-Balat A; Schmeil I; Karn T; Becker S; Sänger N; Holtrich U; Arsenic R
Pathol Oncol Res; 2018 Apr; 24(2):277-282. PubMed ID: 28470574
[TBL] [Abstract][Full Text] [Related]
6. IMP3 expression in human ovarian cancer is associated with improved survival.
Noske A; Faggad A; Wirtz R; Darb-Esfahani S; Sehouli J; Sinn B; Nielsen FC; Weichert W; Buckendahl AC; Röske A; Müller B; Dietel M; Denkert C
Int J Gynecol Pathol; 2009 May; 28(3):203-10. PubMed ID: 19620937
[TBL] [Abstract][Full Text] [Related]
7. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
Rodríguez IM; Prat J
Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
[TBL] [Abstract][Full Text] [Related]
8. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.
Ye F; Hu Y; Zhou C; Hu Y; Chen H
Pathobiology; 2012; 79(6):307-13. PubMed ID: 22688257
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
[TBL] [Abstract][Full Text] [Related]
10. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
12. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
13. IMP3 expression in serous tumors of the ovary.
Chisté M; Alexis J; Recine M
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):658-62. PubMed ID: 25279713
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
15. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes.
Lu L; Wang S; Zhu Q; Qu Y; Gu W; Ning Y; Chen X; Wang Y
Pathol Res Pract; 2018 Aug; 214(8):1087-1094. PubMed ID: 29866423
[TBL] [Abstract][Full Text] [Related]
16. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
17. Mucinous tumors of the ovary: a review.
Hart WR
Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
[TBL] [Abstract][Full Text] [Related]
18. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
Elias KM; Labidi-Galy SI; Vitonis AF; Hornick JL; Doyle LA; Hirsch MS; Cramer DW; Drapkin R
Gynecol Oncol; 2014 Feb; 132(2):328-33. PubMed ID: 24342438
[TBL] [Abstract][Full Text] [Related]
19. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
20. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.
Köbel M; Xu H; Bourne PA; Spaulding BO; Shih IeM; Mao TL; Soslow RA; Ewanowich CA; Kalloger SE; Mehl E; Lee CH; Huntsman D; Gilks CB
Mod Pathol; 2009 Mar; 22(3):469-75. PubMed ID: 19136932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]